- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Medicine
Volume 2012 (2012), Article ID 657694, 4 pages
Refractory Gout Attack
Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo (USP), Avenida Doutor Arnaldo 455, 01246-903 São Paulo, SP, Brazil
Received 11 August 2012; Revised 26 October 2012; Accepted 29 October 2012
Academic Editor: J. W. M. Van der Meer
Copyright © 2012 Simone Fargetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. K. Reinders and T. L. Jansen, “New advances in the treatment of gout: review of pegloticase,” Therapeutics and Clinical Risk Management, vol. 6, pp. 543–550, 2010.
- E. Fels and J. S. Sundy, “Refractory gout: what is it and what to do about it?” Current Opinion in Rheumatology, vol. 20, no. 2, pp. 198–202, 2008.
- D. Becker-Capeller, K. Melker, and M. H. Weber, “The polyarticular gout—change of the clinical picture?” Zeitschrift fur Arztliche Fortbildung, vol. 90, no. 3, pp. 227–231, 1996.
- C. O. Garcia, A. G. Kutzbach, and L. R. Espinoza, “Characteristics of gouty arthritis in the Guatemalan population,” Clinical Rheumatology, vol. 16, no. 1, pp. 45–50, 1997.
- G. V. Lawry II, P. T. Fan, and R. Bluestone, “Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features,” Medicine, vol. 67, no. 5, pp. 335–343, 1988.
- O. L. Meyers and F. S. E. Monteagudo, “Gout in females: an analysis of 92 patients,” Clinical and Experimental Rheumatology, vol. 3, no. 2, pp. 105–109, 1985.
- D. J. McCarty, “Gout without hyperuricemia,” The Journal of the American Medical Association, vol. 271, no. 4, pp. 302–303, 1994.
- N. M. Hadler, W. A. Franck, N. M. Bress, and D. R. Robinson, “Acute polyarticular gout,” American Journal of Medicine, vol. 56, no. 5, pp. 715–719, 1974.
- A. P. Hall, P. E. Barry, T. R. Dawber, and P. M. McNamara, “Epidemiology of gout and hyperuricemia. A long-term population study,” The American Journal of Medicine, vol. 42, no. 1, pp. 27–37, 1967.
- N. Dalbeth and D. O. Haskard, “Mechanisms of inflammation in gout,” Rheumatology, vol. 44, no. 9, pp. 1090–1096, 2005.
- F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006.
- W. J. Martin and J. L. Harper, “Innate inflammation and resolution in acute gout,” Immunology and Cell Biology, vol. 88, no. 1, pp. 15–19, 2010.
- E. Pascual, E. Batlle-Gualda, A. Martínez, J. Rosas, and P. Vela, “Synovial fluid analysis for diagnosis of intercritical gout,” Annals of Internal Medicine, vol. 131, no. 10, pp. 756–759, 1999.
- M. K. Reinders, C. Haagsma, T. L. T. A. Jansen et al., “A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100–200 mg/day in patients with gout,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 892–897, 2009.
- M. H. H. Lee, G. G. Graham, K. M. Williams, and R. O. Day, “A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?” Drug Safety, vol. 31, no. 8, pp. 643–665, 2008.
- M. K. Reinders, E. N. van Roon, T. L. T. A. Jansen et al., “Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 51–56, 2009.
- A. K. Tausche, K. Richter, A. Grässler, S. Hänsel, B. Roch, and H. E. Schröder, “Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor α as a new therapeutic option,” Annals of the Rheumatic Diseases, vol. 63, no. 10, pp. 1351–1352, 2004.
- C. Fiehn and M. Zeier, “Successful treatment of chronic tophaceous gout with infliximab (Remicade),” Rheumatology International, vol. 26, no. 3, pp. 274–276, 2006.
- A. So, T. de Smedt, S. Revaz, and J. Tschopp, “A pilot study of IL-1 inhibition by anakinra in acute gout,” Arthritis Research and Therapy, vol. 9, article R28, 2007.
- R. Terkeltaub, J. S. Sundy, H. R. Schumacher et al., “The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1613–1617, 2009.
- A. So, M. de Meulemeester, A. Pikhlak et al., “Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study,” Arthritis and Rheumatism, vol. 62, no. 10, pp. 3064–3076, 2010.
- I. Walter-Sack, U. Gresser, M. Adjan et al., “Variation of benzbromarone elimination in man—a population study,” European Journal of Clinical Pharmacology, vol. 39, no. 2, pp. 173–176, 1990.
- I. Walter-Sack, J. X. de Vries, A. Ittensohn, and E. Weber, “Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles,” European Journal of Clinical Pharmacology, vol. 39, no. 6, pp. 577–581, 1990.